Education
About Us
Working with TipRanks
Follow Us
Vivesto AB ADR (OASMY)
OTHER OTC:OASMY
OASMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.05
Previous CloseN/A
Volume4.30K
Average Volume (3M)3.00
Market Cap
$13.16M
Enterprise Value$3.14M
Total Cash (Recent Filing)$23.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 11, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 25, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding179,347,820
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vivesto AB ADR News
OASMY FAQ
What was Vivesto AB ADR’s price range in the past 12 months?
Vivesto AB ADR lowest stock price was $0.01 and its highest was $0.05 in the past 12 months.
What is Vivesto AB ADR’s market cap?
Vivesto AB ADR’s market cap is $13.16M.
When is Vivesto AB ADR’s upcoming earnings report date?
Vivesto AB ADR’s upcoming earnings report date is Nov 11, 2025 which is in 33 days.
How were Vivesto AB ADR’s earnings last quarter?
Vivesto AB ADR released its earnings results on Aug 12, 2025. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.006.
Is Vivesto AB ADR overvalued?
According to Wall Street analysts Vivesto AB ADR’s price is currently Overvalued.
Does Vivesto AB ADR pay dividends?
Vivesto AB ADR pays a Notavailable dividend of $0.003 which represents an annual dividend yield of N/A. See more information on Vivesto AB ADR dividends here
What is Vivesto AB ADR’s EPS estimate?
Vivesto AB ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB ADR have?
Vivesto AB ADR has 179,347,820 shares outstanding.
What happened to Vivesto AB ADR’s price movement after its last earnings report?
Vivesto AB ADR reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vivesto AB ADR?
Currently, no hedge funds are holding shares in OASMY
Company Description
Vivesto AB ADR
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Technical Analysis
TherapeuticsMD
―
Aytu BioScience
―
Kala Pharmaceuticals
―
Cosmos Holdings
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---